Arbutus Biopharma Corp License Costs (Deprecated 2018-01-31)
Arbutus Biopharma Corp (ABUS) reported License Costs (Deprecated 2018-01-31) of CAD 1.49 million for the 12-month period ending 2012-12-31, per its 20-F filed 2013-03-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LicenseCosts · last filed 2015-03-13
CAD
| Period end | License Costs (Deprecated 2018-01-31) 2 month | License Costs (Deprecated 2018-01-31) 12 month |
|---|---|---|
| 2012-12-31 | 298.08K CAD 20-F · filed 2013-03-27 | 1.49M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 97.94K CAD 20-F · filed 2013-03-27 |
USD
| Period end | License Costs (Deprecated 2018-01-31) 0 month | License Costs (Deprecated 2018-01-31) 2 month | License Costs (Deprecated 2018-01-31) 12 month |
|---|---|---|---|
| 2012-12-31 | $300.00K 20-F · filed 2013-03-27 | $8.50M 10-K · filed 2015-03-13 | |
| 2012-11-12 | $300.00K 10-K · filed 2015-03-13 | ||
| 2011-12-31 | $100.00K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |